Patrick J. Shenot

Canadian Journal of Urology, Vol.26, No.3, pp. 9781-9781, 2019

Abstract This article has no abstract. More >

Senad Kalkan¹, William I. Jaffe², Vannita Simma-Chiang³, Eric S. W. Li⁴, Jerry G. Blaivas³

Canadian Journal of Urology, Vol.26, No.3, pp. 9774-9780, 2019

Abstract Introduction: There is a paucity of data about augmentation cystoplasty (AC) in multiple sclerosis (MS) patients with refractory lower urinary tract symptoms (LUTS). The aim of this study is to evaluate the long term outcomes and morbidity of these procedures in MS patients.
Materials and methods: This is a retrospective observational study of consecutive patients (1984-2017) with MS and refractory LUTS who underwent AC with or without a continent/incontinent abdominal stoma or urinary diversion. Pre and postoperative evaluations included routine labs, videourodynamic studies (VUDS), cystoscopy, and upper tract imaging. Long term outcomes and complications were assessed by… More >

Matthew R. Epstein, Thomas F. Monaghan, Johnathan A. Khusid, Nicholas R. Suss, Christina W. Agudelo, Kyle P. Michelson, Zhan D. Wu, Fred Gong, Jeffrey P. Weiss

Canadian Journal of Urology, Vol.26, No.3, pp. 9769-9773, 2019

Abstract Introduction: Much of what is known about the etiology of nocturia (i.e., nocturnal polyuria [NP], small bladder capacity [SBC], etc.) at the population level stems from the Krimpen study, which enrolled aging males from a homogenous municipality in the Netherlands. Given the higher prevalence of benign prostatic hyperplasia and overactive bladder in black versus white males in population research, we aim to test the hypothesis that black males seeking treatment for lower urinary tract symptoms (LUTS) are more likely to have nocturia owing to SBC.
Materials and methods: We retrospectively analyzed 24-hour frequency-volume charts (FVCs) completed by… More >

Nachiketh Soodana-Prakash¹, R. Patricia Castillo², Isildinha M. Reis^3,4, Radka Stoyanova^3,5, Deukwoo Kwon³, Maria C. Velasquez², Bruno Nahar¹, Pratik Kannabur¹, Taylor A. Johnson¹, Sanjaya K. Swain^1,3, Natalie Ben-Yakar¹, Vivek Venkatramani¹, Chad Ritch^1,3, Ramgopal Satyanarayana^1,3, Mark L. Gonzalgo^1,3, Dipen J. Parekh^1,3, Leonardo Bittencourt⁶, Sanoj Punnen^1,3

Canadian Journal of Urology, Vol.26, No.3, pp. 9763-9768, 2019

Abstract Introduction: To assess the secondary sequence rule in The Prostate Imaging Reporting Data System (PI-RADS) version 2 by comparing the detection of Grade group 1+ (GG1+) and 2+ (GG2+) cancers in PI-RADS 3, an upgraded PI-RADS 4, and true (non-upgraded) PI-RADS 4 targets.
Materials and methods: We analyzed a total of 589 lesions scored as PI-RADS 3 or 4 obtained from 434 men who underwent mpMRI-US fusion biopsy from September 2015 to November 2017 for evaluation of GG1+ and GG2+ prostate cancer. PI-RADS 4 lesions were differentiated into those that were “upgraded” to PI-RADS 4 based on… More >

Syed Alam¹, Joseph Tortora², Ilene Staff², Tara McLaughlin¹, Joseph Wagner¹

Canadian Journal of Urology, Vol.26, No.3, pp. 9758-9762, 2019

Abstract Introduction: OncotypeDx, Prolaris, and Decipher have each been validated to predict outcomes and guide treatment for patients with clinically localized prostate cancer, but they have yet to be compared to one another. Here we assess the correspondence between the results of each.
Materials and methods: We performed a retrospective chart review to identify patients who underwent at least two of the three genomic tests at Hartford Hospital between 2014 and 2017. We used test-specific definitions of a favorable prediction for each to compare the percent agreement between each pair. Results were also compared to treatment recommendations based… More >

Kassem S. Faraj¹, Haidar M. Abdul-Muhsin¹, Anojan K. Navaratnam¹, Kyle M. Rose¹, Jeffrey Stagg², Thai H. Ho³, Alan H. Bryce³, Scott M. Cheney¹, Mark D. Tyson¹, Erik P. Castle¹

Canadian Journal of Urology, Vol.26, No.3, pp. 9752-9757, 2019

Abstract Introduction: The management of malignant mesothelioma of the tunica vaginalis (MMTVT) is not clearly defined. Retroperitoneal lymph node dissection has been reported as a potential management option. Herein we present our experience with robot-assisted retroperitoneal lymph node dissection (RARPLND) in our series of patients with MMTVT.
Materials and methods: The Mayo Clinic cancer registry was queried from 1972-present for all patients who had a diagnosis of MMTVT. Six patients were identified, five of whom were treated with RPLND, where four underwent RARPLND.
Results: In five patients who underwent RPLND, the median age was 50 years (IQR 34-51). Four… More >

Mani Menon

Canadian Journal of Urology, Vol.26, No.3, pp. 9748-9751, 2019

Abstract This article has no abstract. More >

Kevin R. Loughlin

Canadian Journal of Urology, Vol.26, No.3, pp. 9746-9747, 2019

Abstract This article has no abstract. More >

Canadian Journal of Urology, Vol.26, No.4, pp. 9871-9904, 2019

Abstract This article has no abstract. More >

Shu Pan¹, Maria J. D’Amico², Ricardo Munarriz¹

Canadian Journal of Urology, Vol.26, No.4, pp. 9867-9870, 2019

Abstract Intracavernosal self-injection (ICI) is an effective treatment for erectile dysfunction. A rare but serious complication is needle breakage. We report an unusual case of a 51-year-old transgender female patient who did not desire gender-affirming surgery, and used ICI to treat her longstanding erectile dysfunction. She presented to the emergency department 2 months after needle breakage during ICI, and was subsequently successfully treated with intraoperative fluoroscopy and needle fragment extraction. It is important to recognize transgender patients may desire to preserve sexual function, and for providers to engage in discussion surrounding sexual health throughout treatment for More >